Journal

Genes
ISSN: 2073-4425
Titre abrégé: Genes (Basel)
Pays: Switzerland
ID NLM: 101551097

Informations de publication

Date de publication:
23 01 2021
Historique:
received: 18 12 2020
revised: 13 01 2021
accepted: 20 01 2021
entrez: 27 1 2021
pubmed: 28 1 2021
medline: 27 7 2021
Statut: epublish

Résumé

Only a small fraction of hereditary breast and/or ovarian cancer (HBOC) cases are caused by germline variants in the high-penetrance breast cancer 1 and 2 genes (

Identifiants

pubmed: 33498765
pii: genes12020150
doi: 10.3390/genes12020150
pmc: PMC7911518
pii:
doi:

Substances chimiques

Biomarkers, Tumor 0
Tumor Suppressor Proteins 0
BARD1 protein, human EC 2.3.2.27
Ubiquitin-Protein Ligases EC 2.3.2.27

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

J Cancer Res Clin Oncol. 2018 Dec;144(12):2495-2513
pubmed: 30306255
J Mol Diagn. 2020 Apr;22(4):544-554
pubmed: 32068069
Genes (Basel). 2020 Jul 27;11(8):
pubmed: 32726901
Clin Genet. 2016 Mar;89(3):336-40
pubmed: 26010302
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
N Engl J Med. 2015 Jun 4;372(23):2243-57
pubmed: 26014596
Cancer Epidemiol Biomarkers Prev. 2020 Feb;29(2):359-367
pubmed: 31871109
Sci Rep. 2017 Jan 04;7:37984
pubmed: 28050010
Int J Cancer. 2019 Nov 15;145(10):2682-2691
pubmed: 30927264
NPJ Breast Cancer. 2020 Jun 12;6:25
pubmed: 32566746
J Natl Cancer Inst. 2015 Aug 27;107(11):
pubmed: 26315354
Cancer. 2015 Jan 1;121(1):25-33
pubmed: 25186627
BMJ Open. 2018 Mar 27;8(3):e018324
pubmed: 29593016
J Biol Chem. 2008 Jul 25;283(30):21179-86
pubmed: 18480049
Cancer. 2017 May 15;123(10):1721-1730
pubmed: 28085182
JAMA Oncol. 2019 Jan 1;5(1):51-57
pubmed: 30128536
J Natl Cancer Inst. 2018 Aug 1;110(8):855-862
pubmed: 30099541
Gynecol Oncol. 2017 Nov;147(2):375-380
pubmed: 28888541
Nature. 2020 May;581(7809):434-443
pubmed: 32461654
Breast Cancer Res Treat. 2016 Apr;156(3):507-515
pubmed: 27083178
Oncogene. 2005 May 26;24(23):3726-36
pubmed: 15782130
Hum Mutat. 2016 Jun;37(6):564-9
pubmed: 26931183
Biochemistry. 2007 Jul 3;46(26):7706-12
pubmed: 17550235
Breast Cancer Res Treat. 2020 Jun;181(2):465-473
pubmed: 32318955
Gynecol Oncol. 2018 Dec;151(3):481-488
pubmed: 30322717
JAMA Oncol. 2017 Sep 1;3(9):1190-1196
pubmed: 28418444
Eur J Hum Genet. 2020 Dec;28(12):1645-1655
pubmed: 32561899
Sci Rep. 2017 Jan 04;7:39348
pubmed: 28051113
Breast Cancer Res. 2019 Apr 29;21(1):55
pubmed: 31036035
Nat Genet. 1996 Dec;14(4):430-40
pubmed: 8944023
Mol Cell. 1999 Oct;4(4):511-8
pubmed: 10549283
Genet Med. 2018 Dec;20(12):1677-1686
pubmed: 29988077
Wellcome Open Res. 2016 Nov 25;1:20
pubmed: 28459104
JAMA Oncol. 2016 Apr;2(4):482-90
pubmed: 26720728
Hum Mutat. 2010 Mar;31(3):E1175-85
pubmed: 20077502
NPJ Breast Cancer. 2017 Jun 9;3:22
pubmed: 28649662
J Clin Oncol. 2015 Feb 1;33(4):304-11
pubmed: 25452441
J Biol Chem. 2001 May 4;276(18):14537-40
pubmed: 11278247
Genes (Basel). 2020 Jul 15;11(7):
pubmed: 32679805

Auteurs

Paula Rofes (P)

Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL-IGTP-IDIBGI, 08916 Badalona, Spain.
Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, 08916 Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28929 Madrid, Spain.

Jesús Del Valle (J)

Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL-IGTP-IDIBGI, 08916 Badalona, Spain.
Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, 08916 Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28929 Madrid, Spain.

Sara Torres-Esquius (S)

Hereditary Cancer Genetics Group, Vall d'Hebron Institute of Oncology (VHIO), Medical Oncology Department, University Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.

Lídia Feliubadaló (L)

Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL-IGTP-IDIBGI, 08916 Badalona, Spain.
Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, 08916 Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28929 Madrid, Spain.

Agostina Stradella (A)

Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL-IGTP-IDIBGI, 08916 Badalona, Spain.
Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, 08916 Barcelona, Spain.
Medical Oncology Department, Catalan Institute of Oncology, IDIBELL, 08916 Barcelona, Spain.

José Marcos Moreno-Cabrera (JM)

Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL-IGTP-IDIBGI, 08916 Badalona, Spain.
Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, 08916 Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28929 Madrid, Spain.

Adriana López-Doriga (A)

Oncology Data Analytics Program (ODAP), Catalan Institute of Oncology, 08916 Barcelona, Spain.
Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), 28029 Madrid, Spain.

Elisabet Munté (E)

Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL-IGTP-IDIBGI, 08916 Badalona, Spain.
Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, 08916 Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28929 Madrid, Spain.

Rafael De Cid (R)

Genomes for Life-GCAT Lab Group, IGTP, Institut Germans Trias i Pujol (IGTP), 08916 Badalona, Spain.

Olga Campos (O)

Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL-IGTP-IDIBGI, 08916 Badalona, Spain.
Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, 08916 Barcelona, Spain.

Raquel Cuesta (R)

Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL-IGTP-IDIBGI, 08916 Badalona, Spain.
Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, 08916 Barcelona, Spain.

Álex Teulé (Á)

Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL-IGTP-IDIBGI, 08916 Badalona, Spain.
Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, 08916 Barcelona, Spain.

Èlia Grau (È)

Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL-IGTP-IDIBGI, 08916 Badalona, Spain.
Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, 08916 Barcelona, Spain.

Judit Sanz (J)

Genetic Counselling Unit, Medical Oncology Department, Althaia Xarxa Assistencial Universitària de Manresa, 08243 Manresa, Spain.

Gabriel Capellá (G)

Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL-IGTP-IDIBGI, 08916 Badalona, Spain.
Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, 08916 Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28929 Madrid, Spain.

Orland Díez (O)

Catalan Health Institute, Vall d'Hebron Hospital Universitari, 08035 Barcelona, Spain.
Hereditary Cancer Genetics Group, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.

Joan Brunet (J)

Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL-IGTP-IDIBGI, 08916 Badalona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28929 Madrid, Spain.
Medical Sciences Department, School of Medicine, University of Girona, 17007 Girona, Spain.

Judith Balmaña (J)

Hereditary Cancer Genetics Group, Vall d'Hebron Institute of Oncology (VHIO), Medical Oncology Department, University Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.

Conxi Lázaro (C)

Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL-IGTP-IDIBGI, 08916 Badalona, Spain.
Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, 08916 Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28929 Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH